Previously, Moderna’s COVID-19 vaccine (mRNA-1273) was only available for this younger age group under an Emergency Use Authorization (EUA).
The event highlighted the company’s progress in developing a fully integrated and localized AI+mRNA platform that accelerates the creation of innovative therapies, particularly in cancer and autoimmune diseases.
Under the deal, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across major markets including North America, Europe, Japan, and Greater China.
Merck aims to enhance its respiratory portfolio with the acquisition of Ohtuvayre (ensifentrine), a newly approved inhaled treatment for chronic obstructive pulmonary disease (COPD), also known as “smoker’s lung.”
Charité and Siemens Healthineers will launch joint research projects to create faster and more precise diagnostic and treatment methods using AI.
Across all three trials, efsitora demonstrated non-inferior reductions in A1C levels compared to standard daily basal insulins.
The partnership resulted in a unique educational program that incorporates insights from the Moscow Experiment, a groundbreaking project in AI for medical imaging.
The agreement grants Chugai exclusive worldwide rights to research, develop, manufacture, and sell antibodies derived from the identified targets.
This decision is aimed at ensuring the swift and efficient delivery of Novo Nordisk’s promised investment of over 2 billion euros (US$2.34 billion) in a manufacturing facility located south of Rome.